GlassScriptPhysician profile
J D Dumas
NPI 1548333610
$11,665.69
in general payments reported to CMS, 2019-2025
44 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,129 · 2020: $1,127 · 2021: $1,423 · 2022: $1,825 · 2023: $2,029 · 2024: $1,651 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,162.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,361.73 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,029.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $919.17 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $910.11 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $908.01 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $727.27 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $672.65 | 2019-2025 | Evenity, Repatha, Otezla |
| Tris Pharma INC | $495.77 | 2019-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $481.94 | 2019-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $452.09 | 2019-2025 | Jardiance |
| Axsome Therapeutics, INC. | $425.55 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $411.28 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Corium, LLC | $368.29 | 2022-2025 | Azstarys |
| Allergan, INC. | $338.84 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $223.32 | 2019-2024 | Rexulti |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Dumas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.